135 related articles for article (PubMed ID: 38614979)
1. Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
Gill J; Yendamuri K; Chatterjee U; Yao S; Oladeru OT; Singh AK; Ma SJ
BMC Cancer; 2024 Apr; 24(1):461. PubMed ID: 38614979
[TBL] [Abstract][Full Text] [Related]
2. Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptor-Positive Breast Cancer.
Ma SJ; Gill J; Waldman O; Yendamuri K; Dunne-Jaffe C; Chatterjee U; Fekrmandi F; Shekher R; Iovoli A; Yao S; Oladeru OT; Singh AK
JAMA Netw Open; 2023 Feb; 6(2):e230179. PubMed ID: 36809469
[TBL] [Abstract][Full Text] [Related]
3. Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
Ma SJ; Gill J; Yendamuri K; Chatterjee U; Waldman O; Dunne-Jaffe C; Fekrmandi F; Shekher R; Iovoli A; Yao S; Oladeru OT; Singh AK
BMC Cancer; 2023 Apr; 23(1):330. PubMed ID: 37041481
[TBL] [Abstract][Full Text] [Related]
4. Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score.
Huang HC; Calip GS; Weiss J; Simons Y; Gadi VK; Danciu OC; Rauscher GH; Hoskins KF
J Natl Compr Canc Netw; 2024 Jan; 22(1D):e237077. PubMed ID: 38190799
[TBL] [Abstract][Full Text] [Related]
5. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
[TBL] [Abstract][Full Text] [Related]
8. Racial/Ethnic Differences and Trends in Pathologic Complete Response Following Neoadjuvant Chemotherapy for Breast Cancer.
Ma SJ; Serra LM; Yu B; Farrugia MK; Iovoli AJ; Yu H; Yao S; Oladeru OT; Singh AK
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158802
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy.
Ma SJ; Serra LM; Yu B; Bartl AJ; Farrugia MK; Oladeru OT; Singh AK
Breast Cancer Res Treat; 2021 Oct; 189(3):737-745. PubMed ID: 34519904
[TBL] [Abstract][Full Text] [Related]
10. Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysis.
Stabellini N; Cao L; Towe CW; Amin AL; Montero AJ
Cancer Med; 2023 Oct; 12(19):19607-19616. PubMed ID: 37766666
[TBL] [Abstract][Full Text] [Related]
11. Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Han Y; Miao ZF; Lian M; Peterson LL; Colditz GA; Liu Y
Breast Cancer Res Treat; 2020 Dec; 184(3):915-925. PubMed ID: 32929567
[TBL] [Abstract][Full Text] [Related]
12. 21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy.
Chevli N; Haque W; Tran KT; Farach AM; Schwartz MR; Hatch SS; Butler EB; Teh BS
Radiother Oncol; 2022 Sep; 174():37-43. PubMed ID: 35772577
[TBL] [Abstract][Full Text] [Related]
13. Socioecologic Factors and Racial Differences in Breast Cancer Multigene Prognostic Scores in US Women.
Parab AZ; Kong A; Lee TA; Kim K; Nutescu EA; Malecki KC; Hoskins KF; Calip GS
JAMA Netw Open; 2024 Apr; 7(4):e244862. PubMed ID: 38568689
[TBL] [Abstract][Full Text] [Related]
14. Racial Differences in Time to Breast Cancer Surgery and Overall Survival in the US Military Health System.
Eaglehouse YL; Georg MW; Shriver CD; Zhu K
JAMA Surg; 2019 Mar; 154(3):e185113. PubMed ID: 30673075
[TBL] [Abstract][Full Text] [Related]
15. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
16. Genomic expression assay testing among American Indian and Alaska Native women with breast cancer.
Marmor S; Longacre CF; Altman AM; Hui JYC; Jensen EH; Tuttle TM
Cancer; 2020 Dec; 126(24):5222-5229. PubMed ID: 32926435
[TBL] [Abstract][Full Text] [Related]
17. Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer.
Hoskins KF; Calip GS; Huang HC; Ibraheem A; Danciu OC; Rauscher GH
JAMA Oncol; 2023 Apr; 9(4):536-545. PubMed ID: 36795405
[TBL] [Abstract][Full Text] [Related]
18. Racial disparities in incidence, treatment, and survival in adult brain metastases: a 10-year national database analysis.
Jiang SH; Bhaskara M; Deysher D; Sadeh M; Souter J; Mehta AI
Neurosurg Focus; 2023 Nov; 55(5):E6. PubMed ID: 37913546
[TBL] [Abstract][Full Text] [Related]
19. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
[TBL] [Abstract][Full Text] [Related]
20. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
Holowatyj AN; Cote ML; Ruterbusch JJ; Ghanem K; Schwartz AG; Vigneau FD; Gorski DH; Purrington KS
J Clin Oncol; 2018 Mar; 36(7):652-658. PubMed ID: 29341832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
